Hitoshi Shibuya

Ovarian obturator hernia

7 Sculpher MJ, Drummond MF, Buxton MJ. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997; 2: 26–30. 8 Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 342–64. 9 Briggs A, Sculpher MJ. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397–409. 10 Neumann PJ, Hermann RC, Kuntz KM. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 1999; 52: 1138–45. 11 Clegg A, Bryant J, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic review. Health Technol Assess 2000; 5: 1–137. 12 Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993; 13: 322–38. 13 Sherlaw-Johnson A. Cytological screening and management of abnormalities in prevention of cervical canser: and overview with stochastic modelling. J Clin Pathol 1994; 47: 430–35. 14 Fitzpatrick R, Shortall E, Sculpher M, et al. Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess 1998; 2: 1–64. 15 Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making 1986; 6: 85–92. 16 Fenwick E, Claxton K, Sculpher M, Briggs A. Improving the efficiency and relevance of health technology assessment: the role of decision analytic modelling (Centre for Health Economics discussion paper 179). York: Centre for Health Economics, University of York, 2000. 17 Claxton K, Neuman PJ, Araki SS, et al. The value of information: an application to a policy model of Alzheimer’s disease. Int J Technol Assess Health Care 2001; 17: 38–55. 18 Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996; 5: 513–24. 19 Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998; 18: 95–109. 20 Thompson KM, Evans JS. The value of improved national exposure information for perchloroethylene (perc): a case study for dry cleaners. Risk Anal 1997; 17: 253–71. 21 Claxton K, Neumann P, Araki S, et al. The efficient design of clinical trials: an application to the evaluation of treatment strategies for Alzheimer’s disease. Med Decis Making 1999; 19: 4 (abstr). 22 Neumann PJ, Claxton K, Weinstein MC. The FDA’s regulation of health economic information. Health Aff 2000; 19: 129–37. VIEWPOINT